Notice for vutrisiran (Medison Pharma Australia Pty Ltd)
Active ingredients
vutrisiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for injection
Indication
Treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)
Therapeutic area
Cardiovascular